Biotech Startups

IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.

5 investors

IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases. The company uses its proprietary SEQ SIFTER™ platform to develop first-in-class therapeutic antibodies targeting allergic cascades.

5 investors

Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy. It focuses on therapies for patients with limited treatment options in cardiometabolic and cardiovascular conditions.

5 investors

ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation. Its programs address cancer, infectious disease, and autoimmune disease.

5 investors

Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.

5 investors

ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.

5 investors

Immunis Biomedical develops multi-active biologics based on stem cell-derived secretomes — cell-free therapeutics containing proteins, lipids and growth factors — aimed at treating age-related and immune-related diseases. Its approach targets multiple biological pathways at once rather than a single protein or mechanism.

5 investors

Immunophotonics is a clinical-stage biotech company developing novel treatments for solid-tumor cancers and infectious diseases by combining tumor ablation with systemic cancer immunotherapy. The company's intellectual property platform includes IP-001, designed to transform routine ablation procedures into systemically active cancer immunotherapy.

5 investors

Immuto Scientific uses patient-derived tissue models combined with computational structural proteomics and machine learning to identify disease-specific protein targets for drug discovery. The platform applies advanced mass spectrometry and molecular simulations to distinguish diseased from healthy tissues and accelerate therapeutic development.

5 investors

Inceptive builds foundation models of biological systems for drug discovery, specializing in sequence-based medicines like mRNA and peptides. The company combines deep learning trained on heterogeneous life data with in-house wet lab validation to design novel drug candidates that outperform existing options.

5 investors

Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings. The company's diagnostic platform serves healthcare providers treating acutely ill patients, with applications extending to emerging infectious diseases, autoimmune conditions, and transplant rejection.

5 investors

5 investors

Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data. The company targets the development of treatments for challenging diseases through membrane-permeable and orally available compounds.

5 investors

InSilicoTrials provides a platform for clinical trial simulation and design optimization using mechanistic models, AI, and digital twins. The platform helps pharmaceutical companies, biotech firms, and regulators reduce development risk and accelerate the path from drug discovery to patient access.

5 investors

Intact Vascular develops interventional vascular medical devices intended for use by physicians trained in interventional techniques. The company is associated with Philips.

5 investors

IntegriCulture is a Japanese cellular agriculture company developing cell-culture systems and production technology for cultured foods, along with OEM/ODM cosmetics and supplements and sales of cell-culture consumables and equipment. It applies its "CulNet"/cell-culture technology to help address protein supply and offers products across the food and cosmetics sectors.

5 investors

InterVenn applies glycoproteomics combined with artificial intelligence to study women's health conditions such as ovarian cancer and endometriosis, mapping glycoprotein control points linked to disease progression. It works with research partners and clinical organizations to integrate its glycoproteomic insights into healthcare and clinical workflows.

5 investors

Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases. The page presents investor relations content including financial results and corporate governance updates.

5 investors

Invert provides infrastructure and intelligence software that connects bioprocess equipment and data sources for pharmaceutical and biologics companies, enabling faster process development and manufacturing through integrated data platforms and digital twin capabilities.

5 investors

Isomorphic Labs applies artificial intelligence to drug discovery, working to develop treatments for serious diseases. It operates in the biotech and AI space.

5 investors

Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.

5 investors

Kaleidoscope provides a software platform for scientific R&D teams to track and communicate project data, manage complex research processes, and accelerate decision-making. The platform serves biotech and engineering teams seeking alternatives to fragmented spreadsheet-based workflows.

5 investors

Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.

5 investors

Latch builds data infrastructure and software tools for biological computing, enabling researchers to program and automate biological discovery through high-throughput laboratory automation and machine learning.

5 investors